Navigation Links
Synthes and Lilly Sign Development and Collaboration Agreement
Date:6/9/2011

onal strengths of each partner," said Michel Orsinger, president and CEO of Synthes. "Osteoporosis is one of the most significant unsolved clinical problems in orthopedics. Addressing the osteoporosis disease as well as the resulting fracture and bone defect is a significant strategic priority of both organizations," he continued. "Strategic collaborations between medtech and pharma companies represent a new and promising avenue to develop and market true innovations in a changing, dynamic market environment."

"We believe that patients worldwide will benefit from this collaboration because together we will be able to look for new ways to treat osteoporosis and bone fractures," said Bryce Carmine, executive vice president and president, Lilly Bio-Medicines, Eli Lilly and Company. "At Lilly, we are always exploring new opportunities to bring innovative medicines to people with unmet medical needs and improve outcomes for individual patients."

"Many orthopedic surgeons are in the position to diagnose and treat osteoporosis when their patients present with fractures, and we believe it is imperative to treat the underlying cause of the initial fracture," said Johnston Erwin, Bone/Muscle/Joint global development platform leader, Lilly Bio-Medicines, Eli Lilly and Company. "Our collaboration will also explore ways to treat fractures with Forteo in older patients and/or those who have osteoporosis and, longer term, will look for new ways to deliver medicine locally to the fracture site."

Financial terms of the agreement have not been disclosed.

Forteo, an FDA-approved osteoporosis therapy to help build new bone, is a treatment for postmenopausal women with osteoporosis who are at high risk for fracture(1) and to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.(2) Individuals at high risk for having broken bones include men and women with either a history of broken bones due to osteoporosis, who
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BGI Releases a Complete De Novo E. Coli O104 Genome Assembly and is Making Its Detection Kit Protocols and Synthesized Primers Freely Available to Worldwide Disease Control and Research Agencies
2. Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create Worlds Most Innovative and Comprehensive Orthopaedics Business
3. Hologics Selenia Dimensions (3-D) Digital Mammography Tomosynthesis System Receives Favorable Votes From FDA Advisory Panel
4. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
5. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
6. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
7. Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas
8. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
9. Lilly Comments on Court Ruling in Amylin Litigation
10. Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement
11. Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... focused on the development and commercialization of novel bile ... the pricing of an underwritten public offering of 1,730,000 ... price of $33.01 per share.  In addition, Intercept has ... to an additional 259,500 shares of common stock. ...
(Date:6/18/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: ... announced public offering of common shares (the "Offering"). Pursuant ... shares at a price of $85.00 per share, for ... will file a final prospectus supplement to its effective ... a similar filing with the securities regulatory authorities in ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... Sept. 16 Boston Scientific Corporation (NYSE: ... Drug Administration (FDA) has approved an expanded indication for ... CRT-D.  The exclusive expanded indication is effective immediately and ... the FDA for patients in all New York Heart ...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory ... do not adequately demonstrate that the potential benefits of ... a population of overweight and obese individuals to allow ...
Cached Medicine Technology:Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 2Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 3Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 4Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 2Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 3Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 4
(Date:6/18/2013)... New York (PRWEB) June 18, 2013 ... dedicated to protecting the rights of victims injured by ... University’s independent review of Medtronic’s Infuse bone graft products ... Internal Medicine, a medical journal, the two studies serve ... difference in effectiveness” when comparing Infuse and the traditional ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
(Date:6/18/2013)... shown that cancer cells have a much different ... scientists at The University of Texas at Dallas have ... strategy to combat lung cancer. , In an article ... ONE , UT Dallas researchers compared the metabolic characteristics ... taken from the same patient. , They found ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ages 13 ... for Disease Control and Prevention (CDC). Of those, nearly 20 ... HIV Testing Day on June 27, Allsup, a nationwide provider ... CDC and other organizations are raising awareness of the importance ... new HIV infections each year. Along with developing AIDS, those ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from respiratory ... of a silicone treatment for gluteus augmentation at Cuerpos Health ... by a mystery Venezuelan doctor in a center that was ... Vazquez of Bayshore Cosmetic Surgery , women suffering from ... not board certified is more common than people think. ...
Breaking Medicine News(10 mins):Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... Defend Intellectual Property RightsINDIANAPOLIS, March 9 Eli Lilly ... the following statement after being granted a temporary restraining ... of Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals. Teva ... version prior to the resolution of outstanding patent litigation ...
... Neogen Corporation (Nasdaq: NEOG ) announced ... common stock repurchase program. In December, Neogen,s Board of ... have been, and additional shares are expected to be, ... depending on market conditions and other factors. Accordingly, there ...
... renders melanomas sensitive to retinoic acid and stops tumor ... cancer therapies such as radiotherapy, chemotherapy, and retinoic acid ... the prognosis for patients is often poor. However, Vincent ... the National Institutes of Health in Bethesda, Maryland, have ...
... Akerman Senterfitt today announced that Julie Gallagher has joined ... Healthcare Practice Group. Ms. Gallagher,s work focuses on ... companies, individual health care providers and health care facilities. ... she spent seven years as a shareholder."We are very ...
... to Announce Fiscal Third Quarter Results on ... Allscripts-Misys Healthcare Solutions, Inc. ("Allscripts") announced today ... to sell its Medication Services business to ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO )The transaction, which is anticipated ...
... Inc. (Nasdaq: KERX ) today announced that ... Listings Qualification Panel ("Panel") the determination of The Nasdaq ... The Nasdaq Capital Market due to noncompliance with Nasdaq ... a minimum of $2,500,000 in stockholders, equity, or $35,000,000 ...
Cached Medicine News:Health News:Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene 2Health News:Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene 3Health News:Neogen Reactivates Share Repurchase Program 2Health News:JCI online early table of contents: March 9, 2009 2Health News:JCI online early table of contents: March 9, 2009 3Health News:JCI online early table of contents: March 9, 2009 4Health News:JCI online early table of contents: March 9, 2009 5Health News:Julie Gallagher Joins Akerman Senterfitt's Healthcare Practice 2Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 2Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 3Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 4Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 2Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: